2023 Q1 Form 10-K Financial Statement
#000089843223000193 Filed on March 31, 2023
Income Statement
Concept | 2023 Q1 | 2022 Q4 | 2022 |
---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $278.1K | $10.00K | $35.39K |
YoY Change | 969.77% | ||
% of Gross Profit | |||
Research & Development | |||
YoY Change | |||
% of Gross Profit | |||
Depreciation & Amortization | |||
YoY Change | |||
% of Gross Profit | |||
Operating Expenses | $278.1K | $10.00K | $35.39K |
YoY Change | 969.77% | ||
Operating Profit | -$35.39K | ||
YoY Change | 969.77% | ||
Interest Expense | $420.0K | ||
YoY Change | |||
% of Operating Profit | |||
Other Income/Expense, Net | |||
YoY Change | |||
Pretax Income | $140.0K | -$10.00K | -$40.00K |
YoY Change | |||
Income Tax | $29.32K | ||
% Of Pretax Income | 20.94% | ||
Net Earnings | $110.3K | -$10.00K | -$35.39K |
YoY Change | -87643.65% | 969.77% | |
Net Earnings / Revenue | |||
Basic Earnings Per Share | $0.02 | -$0.01 | |
Diluted Earnings Per Share | $0.02 | $0.00 | $0.00 |
COMMON SHARES | |||
Basic Shares Outstanding | 9.055M shares | 1.500M | |
Diluted Shares Outstanding | 5.231M | 1.500M |
Balance Sheet
Concept | 2023 Q1 | 2022 Q4 | 2022 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $350.0K | $120.0K | $120.0K |
YoY Change | |||
Cash & Equivalents | $348.8K | $124.5K | |
Short-Term Investments | |||
Other Short-Term Assets | $80.00K | ||
YoY Change | |||
Inventory | |||
Prepaid Expenses | $81.07K | ||
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $429.9K | $124.5K | $120.0K |
YoY Change | 2517.22% | ||
LONG-TERM ASSETS | |||
Property, Plant & Equipment | |||
YoY Change | |||
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | $70.63M | ||
YoY Change | |||
Other Assets | $0.00 | $1.100M | $1.100M |
YoY Change | 57.14% | ||
Total Long-Term Assets | $70.63M | $1.101M | $1.110M |
YoY Change | 57.26% | 56.34% | |
TOTAL ASSETS | |||
Total Short-Term Assets | $429.9K | $124.5K | $120.0K |
Total Long-Term Assets | $70.63M | $1.101M | $1.110M |
Total Assets | $71.06M | $1.226M | $1.230M |
YoY Change | 73.86% | 73.24% | |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $390.0K | $30.00K | $30.00K |
YoY Change | |||
Accrued Expenses | $0.00 | $10.00K | $10.00K |
YoY Change | -96.55% | ||
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $1.200M | $1.200M |
YoY Change | 200.0% | ||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $403.4K | $1.263M | $1.260M |
YoY Change | 78.64% | 77.46% | |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | |||
YoY Change | |||
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
YoY Change | |||
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $403.4K | $1.263M | $1.260M |
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
Total Liabilities | $2.473M | $1.263M | $1.260M |
YoY Change | 78.64% | 77.46% | |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$1.830M | -$62.51K | |
YoY Change | 130.49% | ||
Common Stock | $216.00 | $173.00 | |
YoY Change | 0.0% | ||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | -$1.830M | -$37.51K | -$40.00K |
YoY Change | |||
Total Liabilities & Shareholders Equity | $71.06M | $1.226M | $1.230M |
YoY Change | 73.86% | 73.24% |
Cashflow Statement
Concept | 2023 Q1 | 2022 Q4 | 2022 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | $110.3K | -$10.00K | -$35.39K |
YoY Change | -87643.65% | 969.77% | |
Depreciation, Depletion And Amortization | |||
YoY Change | |||
Cash From Operating Activities | -$48.43K | $0.00 | -$4.235K |
YoY Change | 38333.33% | 818.66% | |
INVESTING ACTIVITIES | |||
Capital Expenditures | |||
YoY Change | |||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | -$70.21M | ||
YoY Change | |||
Cash From Investing Activities | -$70.21M | ||
YoY Change | |||
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | $70.48M | 50.00K | $124.0K |
YoY Change | 599170.7% | -600.0% | -315.86% |
NET CHANGE | |||
Cash From Operating Activities | -$48.43K | 0.000 | -$4.235K |
Cash From Investing Activities | -$70.21M | ||
Cash From Financing Activities | $70.48M | 50.00K | $124.0K |
Net Change In Cash | $224.3K | 50.00K | $119.7K |
YoY Change | 1827.81% | -600.0% | -306.83% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$48.43K | $0.00 | -$4.235K |
Capital Expenditures | |||
Free Cash Flow | |||
YoY Change |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2022 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2022 | dei |
Document Type
DocumentType
|
10-K | |
CY2022 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
CY2022 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2022-12-31 | |
CY2022 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2022 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2022 | |
CY2022 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2022 | dei |
Entity Registrant Name
EntityRegistrantName
|
BELLEVUE LIFE SCIENCES ACQUISITION CORP. | |
CY2022 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2022 | dei |
Entity File Number
EntityFileNumber
|
001-41390 | |
CY2022 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
84-5052822 | |
CY2022 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
10900 NE 4th Street | |
CY2022 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 2300 | |
CY2022 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Bellevue | |
CY2022 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
WA | |
CY2022 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
98004 | |
CY2022 | dei |
City Area Code
CityAreaCode
|
425 | |
CY2022 | dei |
Local Phone Number
LocalPhoneNumber
|
635-7700 | |
CY2022 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2022 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2022 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2022 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2022 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2022 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | |
CY2022 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2022 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | |
CY2022 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
false | |
CY2022 | dei |
Entity Shell Company
EntityShellCompany
|
true | |
CY2022Q2 | dei |
Entity Public Float
EntityPublicFloat
|
0 | usd |
CY2023Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
9055000 | shares |
CY2022 | dei |
Auditor Name
AuditorName
|
WithumSmith+Brown, PC | |
CY2022 | dei |
Auditor Location
AuditorLocation
|
New York, New York | |
CY2022 | dei |
Auditor Firm
AuditorFirmId
|
100 | |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
124501 | usd |
CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
4757 | usd |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
124501 | usd |
CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
4757 | usd |
CY2022Q4 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
1101353 | usd |
CY2021Q4 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
700330 | usd |
CY2022Q4 | us-gaap |
Assets
Assets
|
1225854 | usd |
CY2021Q4 | us-gaap |
Assets
Assets
|
705087 | usd |
CY2022Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
34000 | usd |
CY2021Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
2847 | usd |
CY2022Q4 | blac |
Accrued Offering Costs Current
AccruedOfferingCostsCurrent
|
12362 | usd |
CY2021Q4 | blac |
Accrued Offering Costs Current
AccruedOfferingCostsCurrent
|
294360 | usd |
CY2022Q4 | us-gaap |
Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
|
1200000 | usd |
CY2021Q4 | us-gaap |
Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
|
400000 | usd |
CY2022Q4 | us-gaap |
Due To Affiliate Current
DueToAffiliateCurrent
|
17000 | usd |
CY2021Q4 | us-gaap |
Due To Affiliate Current
DueToAffiliateCurrent
|
10000 | usd |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1263362 | usd |
CY2021Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
707207 | usd |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
1263362 | usd |
CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
707207 | usd |
CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | shares |
CY2021Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2021Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2021Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
1725000 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
1725000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
1725000 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
1725000 | shares |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
173 | usd |
CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
173 | usd |
CY2022Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
24827 | usd |
CY2021Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
24827 | usd |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-62508 | usd |
CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-27120 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-37508 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2120 | usd |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1225854 | usd |
CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
705087 | usd |
CY2022 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
35388 | usd |
CY2021 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
3308 | usd |
CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-35388 | usd |
CY2021 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3308 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-35388 | usd |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3308 | usd |
CY2022 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
1500000 | shares |
CY2021 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
1500000 | shares |
CY2022 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.01 | |
CY2021 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0 | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1188 | usd |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3308 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2120 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-35388 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-37508 | usd |
CY2022 | us-gaap |
Profit Loss
ProfitLoss
|
-35388 | usd |
CY2021 | us-gaap |
Profit Loss
ProfitLoss
|
-3308 | usd |
CY2022 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
31153 | usd |
CY2021 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
2847 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-4235 | usd |
CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-461 | usd |
CY2022 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
683021 | usd |
CY2021 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
167435 | usd |
CY2022 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
800000 | usd |
CY2021 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
100000 | usd |
CY2022 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
10000 | usd |
CY2022 | us-gaap |
Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
|
17000 | usd |
CY2021 | us-gaap |
Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
|
10000 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
123979 | usd |
CY2021 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-57435 | usd |
CY2022 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
119744 | usd |
CY2021 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-57896 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
4757 | usd |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
62653 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
124501 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
4757 | usd |
CY2022 | blac |
Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
|
12362 | usd |
CY2021 | blac |
Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
|
294360 | usd |
CY2022Q4 | blac |
Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
|
1 | pure |
CY2023Q1 | us-gaap |
Share Price
SharePrice
|
10 | |
CY2023Q1 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
9000000 | usd |
CY2022 | blac |
Percentage Of Trust Account Required For Business Combination
PercentageOfTrustAccountRequiredForBusinessCombination
|
0.80 | pure |
CY2022 | blac |
Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination
ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination
|
0.50 | pure |
CY2022Q4 | us-gaap |
Common Stock Held In Trust
CommonStockHeldInTrust
|
70207500000000 | usd |
CY2022Q4 | blac |
Net Tangible Assets
NetTangibleAssets
|
5000001 | usd |
CY2022 | blac |
Redemption Limit Percentage
RedemptionLimitPercentage
|
0.15 | pure |
CY2022 | blac |
Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
|
1 | pure |
CY2022 | blac |
Period To Consummate Business Combination
PeriodToConsummateBusinessCombination
|
P9M | |
CY2022 | blac |
Maximum Allowed Dissolution Expenses
MaximumAllowedDissolutionExpenses
|
100000 | usd |
CY2022Q4 | us-gaap |
Cash
Cash
|
124501 | usd |
CY2022Q4 | us-gaap |
Debt Current
DebtCurrent
|
1138861 | usd |
CY2022 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-weight: bold;">Use of Estimates</div><div style="font-weight: normal;"><br/> </div><div style="text-align: justify; text-indent: 36pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-weight: normal;">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements and the reported amounts of expenses during the reporting period.</div><div style="font-weight: normal;"><br/> </div><div style="text-align: justify; text-indent: 36pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-weight: normal;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</div><div style="font-weight: normal;"><br/> </div> | |
CY2022Q4 | us-gaap |
Cash
Cash
|
124501 | usd |
CY2022Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
0 | usd |
CY2021Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
0 | usd |
CY2022 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-weight: bold;">Concentration of Credit Risk</div><div style="font-weight: normal;"><br/> </div><div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; color: rgb(35, 31, 32); font-weight: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of</span><span style="font-weight: normal; font-size: 10pt;"> <span style="font-family: 'Times New Roman',Times,serif; color: rgb(35, 31, 32);">$250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</span></span></div><div style="font-weight: normal;"><br/> </div> | |
CY2021Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2022 | us-gaap |
Administrative Fees Expense
AdministrativeFeesExpense
|
7500 | usd |
CY2022Q4 | blac |
Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
|
2 | pure |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2021Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2022 | us-gaap |
Common Stock Voting Rights
CommonStockVotingRights
|
Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders. | |
CY2022Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
0 | usd |
CY2021Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
0 | usd |
CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2022 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2022 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001840425 |